The third Hong Kong Shopping Festival extends into ASEAN for the first time 
Focus Graphite Achieves up to 98.7% Carbon Concentrate Through Mechanical Processing and Activates Downstream Qualification Platform 
DD.NYC Launches Full-Service Video Production Division 
Launchit Solutions and Privacy Horizon Partner to Help Canadian Health Tech Companies Build, Govern, and Scale with Confidence 
DesignRush Podcast, Carla Johnson Examines Why Innovation Claims Fail With Buyers Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting…
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and…
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward…
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
– Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated…